Tradestie Institutional Equity Comparison Engine

SLS vs CGEN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CGEN Overall Edge

CGEN Captures Institutional Edge (2โ€“2 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Compugen Ltd (CGEN) driven by superior Valuation, Growth & Margin while SLS counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, SLS trades at N/M Forward P/E with 0.0% operating margin (-82.5% YoY revenue) versus CGEN at 12.4x Forward P/E and 41.3% operating margin (+102.1% YoY). In options structure, SLS sits in BREAKOUT (27th %ile IV; Dealer Gamma Walls on Pro) against CGEN sits in BREAKDOWN (57th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CGEN
SLS N/M vs CGEN 12.4x Fwd P/E
Growth & Margin Winner CGEN
Op Margin 0.0% vs 41.3% ยท YoY -82.5% vs +102.1%
Momentum & Technical Winner SLS
1Y +1239.2% vs +23.2% ยท 52W Pos 76% vs 33%
Options & Structure Winner SLS
BREAKOUT (27th %ile IV) vs BREAKDOWN (57th %ile IV)
SLS NASDAQ
SELLAS Life Sciences Group, Inc. Common Stock
Pharmaceutical Preparations
$19.15
+156.36% 1D
Market Cap $1.5B
1M Return +82.55%
1Y Return +1239.16%
Forward P/E N/M
Unified AI Score
34.1 / 100 SELL
Tech 5.0 Fund 37.0 Flow 66.0 Mom 38.9
CGEN NASDAQ
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap $193.2M
1M Return +2.54%
1Y Return +23.17%
Forward P/E 12.4x
Unified AI Score
49.8 / 100 HOLD
Tech 53.0 Fund 52.0 Flow 55.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SLS +1239.16% CGEN +23.17% Spread: +1215.99 pp (SLS Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period SLS Revenue CGEN Revenue SLS Op. Margin CGEN Op. Margin Margin Edge
FY2016 N/A $0M N/A -4576.3% CGEN
FY2018 N/A $20M N/A -130.5% CGEN
FY2020 $0M $0M -893.8% -1574.8% SLS
FY2021 $10M $10M -332.8% -584.6% SLS
FY2022 $0M $10M -4195.0% -471.7% CGEN
FY2023 N/A $30M N/A -38.8% CGEN
FY2024 N/A $30M N/A -53.4% CGEN
FY2025 N/A $70M N/A 43.1% CGEN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SLS (2) vs CGEN (8)
Institutional Metric SLS CGEN Criterion Row Winner
Market Capitalization Scale $1.5B $193.2M Larger Scale SLS
Trailing P/E Ratio Valuation N/M 5.2x Lower Multiple CGEN
Forward P/E Ratio Valuation N/M 12.4x Lower Multiple CGEN
Revenue Growth (YoY) Growth -82.5% +102.1% Higher Growth CGEN
Operating Margin (TTM) Profitability 0.0% 41.3% Higher Margin CGEN
Net Profit Margin Profitability 0.0% 47.9% Higher Margin CGEN
Return on Equity (ROE) Capital Efficiency -40.3% 57.2% Higher ROE CGEN
52-Week Range Position Momentum 76% ($1โ€“$25) 33% ($1โ€“$3) Stronger Trend SLS
Beta / 30D Volatility Risk Regime 1.30ฮฒ ยท 544% Vol 1.44ฮฒ ยท 62% Vol Lower Realized Risk CGEN
Unified Institutional Score Composite Signal 34.1 / 100 (SELL) 49.8 / 100 (HOLD) Higher Composite CGEN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SLS vs CGEN Buy Guide
SLS BREAKOUT
99d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 27th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live SLS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CGEN BREAKDOWN
143d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 57th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CGEN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SLS nor CGEN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.